Alto neuroscience inc ANRO.US Overview Analysis
ANRO AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
ANRO Current Performance
0.92%
Alto neuroscience inc
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to ANRO
- NTLA Intellia therapeutics incValue 4Trend 2Swing Trading 5Whale Interest 3Dividend 1See more
ANRO Profile
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. Through insights derived from the Company's scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. The advanced programs are supported by prospectively replicated evidence of clinical activity in biomarker-characterized populations.